Completed dosing of 115 participants in a bioavailability and bioequivalence (BA/BE) clinical trial in Australia for IHL-42X, an investigational treatment for obstructive sleep apnea in July 2024.
Otsuka’s IV solutions subsidiary, Otsuka Pharmaceutical Factory, is breaking into the North American market with the help of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback